Eli Lilly Drug Earns Fast-Track FDA Status for Pancreatic Cancer

Indianapolis, Tuesday, 4 August 2026.
Eli Lilly received FDA Breakthrough Therapy designation for olomorasib to treat advanced pancreatic cancer. This marks the drug’s second fast-track status, addressing a fatal condition with no current approved targeted options.